What is Asthma?
Asthma is a chronic inflammatory disorder of the airways characterized by variable and recurring symptoms (wheezing, breathlessness, chest tightness, and cough), reversible airflow obstruction, bronchial hyperresponsiveness, and underlying inflammation involving multiple cell types including mast cells, eosinophils, T lymphocytes, and epithelial cells. 1
Core Pathophysiological Features
The disease manifests through three interconnected mechanisms that determine clinical severity and treatment response:
Airway Inflammation
Multiple cellular elements drive the inflammatory process 1:
- Mast cells, eosinophils, neutrophils (particularly in sudden-onset fatal exacerbations, occupational asthma, and smokers)
- T lymphocytes, macrophages, and epithelial cells
- In susceptible individuals, this inflammation triggers recurrent episodes particularly at night or early morning
Airflow Limitation
The airways narrow through several inflammation-driven changes 1:
- Bronchoconstriction: Bronchial smooth muscle contracts rapidly in response to allergens or irritants
- Airway hyperresponsiveness: Exaggerated bronchoconstrictor response to various stimuli
- Airway edema: Progressive inflammation leads to edema, mucus hypersecretion, and inspissated mucus plugs that further limit airflow
Airway Remodeling
Persistent structural changes can occur 1:
- Sub-basement fibrosis
- Mucus hypersecretion and epithelial cell injury
- Smooth muscle hypertrophy
- Angiogenesis
- Important caveat: Reversibility of airflow limitation may be incomplete in some patients despite treatment
Clinical Presentation
Cardinal Symptoms 2
The hallmark symptoms are:
- Wheeze (diffuse, polyphonic, bilateral, particularly expiratory)
- Shortness of breath
- Chest tightness
- Cough (when predominant without wheeze, termed "cough variant asthma")
Characteristic Pattern
These symptoms are distinguished by being 2:
- Variable and intermittent
- Worse at night
- Provoked by triggers including exercise, allergens, irritants, viral infections, cold air
Critical diagnostic point: Symptoms are associated with widespread but variable airflow obstruction that is often reversible either spontaneously or with treatment 1.
Disease Heterogeneity
Recent evidence reveals asthma is not a single disease but a syndrome with multiple phenotypes 1, 3:
Type 2 (T2) High Asthma
- Characterized by eosinophilic inflammation
- Defined by: absolute eosinophil count ≥300 cells/μL, FeNO ≥25 ppb, and/or sputum eosinophils ≥1-3% 4
- Represents approximately 50% or more of severe asthma cases 4
- Responds well to inhaled corticosteroids and biologic therapies
Type 2 Low Asthma
- Comprises approximately 10-30% of the asthma population 4
- Different inflammatory patterns and therapeutic responses
- May involve neutrophilic inflammation
Allergic Asthma
- Predominantly triggered by allergens
- Associated with atopic conditions (eczema, allergic rhinitis) 2
Etiology and Risk Factors
The development involves interplay between 1:
- Host factors: Particularly genetics
- Environmental exposures: Occurring at crucial times in immune system development
- Gene-environment interactions that are not fully understood 5
Common Triggers 2
- Pollens, dust, feathered or furry animals
- Exercise
- Viral infections
- Chemicals and environmental tobacco smoke
- Aspirin/NSAIDs or beta-blockers
Epidemiology and Burden
- Affects approximately 7.5% of adults and 10% of the European population 6, 7
- Approximately 300 million people worldwide have asthma 8
- Accounts for significant morbidity: emergency visits, hospitalizations, work/school absences
- Severe asthma affects 5-10% of patients with asthma but constitutes nearly half of medical costs 4
Diagnostic Approach
The diagnosis is clinical - there is no confirmatory blood test, radiographic, or histopathological investigation 2. However, objective confirmation is essential:
Required Elements 7, 9
- Characteristic symptoms (as described above)
- Demonstration of reversible airway obstruction using spirometry
- Variable airflow limitation documented over time
Objective Testing 2
- Spirometry: Decreased FEV1 and/or peak expiratory flow (PEF)
- Bronchodilator reversibility testing
- Peak flow variability: ≥20% variability in amplitude with minimum change of 60 L/min
- Bronchial challenge testing (methacholine, mannitol) when spirometry is normal but symptoms persist
Important caveat: Lung function may be normal between episodes of bronchospasm; if repeatedly normal in the presence of symptoms, the diagnosis must be questioned 2.